Literature DB >> 11863097

FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging.

C Franzius1, H E Daldrup-Link, A Wagner-Bohn, J Sciuk, W L Heindel, H Jürgens, O Schober.   

Abstract

BACKGROUND: The aim of this study was to assess the diagnostic ability of positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG-PET) in the detection of recurrences from malignant primary bone tumors compared with conventional imaging. PATIENTS AND METHODS: In 27 patients (6 osteosarcomas, 21 Ewing's sarcomas), 41 FDG-PET examinations performed for diagnosis or exclusion of recurrent disease were evaluated. Conventional imaging techniques consisted of magnetic resonance imaging of the primary tumor site, thoracic computed tomography, and Tc-99m methylene diphosphonate bone scintigraphy. The reference methods were the histopathological analysis and/or the clinical and imaging follow-up.
RESULTS: In 25 examinations reference methods revealed 52 sites of recurrent disease (local n = 7; distant: osseous n = 22, pulmonary n = 13, soft tissue n = 10). On an examination-based analysis FDG-PET had a sensitivity of 0.96, a specificity of 0.81 and an accuracy of 0.90. Corresponding values for conventional imaging were 1.0, 0.56 and 0.82.
CONCLUSIONS: The sensitivity, specificity and accuracy of FDG-PET in the detection of recurrences from osseous sarcomas are high. On an examination-based analysis, FDG-PET had a not significantly lower sensitivity in comparison with conventional imaging. However, FDG-PET showed a small advantage in the detection of osseous and soft-tissue recurrences compared with conventional imaging.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11863097     DOI: 10.1093/annonc/mdf012

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  30 in total

Review 1.  Diagnostic accuracy of ¹⁸F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis.

Authors:  Giorgio Treglia; Marco Salsano; Antonella Stefanelli; Maria Vittoria Mattoli; Alessandro Giordano; Lorenzo Bonomo
Journal:  Skeletal Radiol       Date:  2011-11-10       Impact factor: 2.199

2.  Has PET become an important clinical tool in paediatric imaging?

Authors:  Klaus Hahn; Thomas Pfluger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-05       Impact factor: 9.236

3.  Is PET/CT necessary in paediatric oncology? For.

Authors:  Christiane Franzius; Kai Uwe Juergens; Otmar Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08       Impact factor: 9.236

4.  The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence.

Authors:  Andrea Angelini; Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Giulia Polverari; Giulia Trovarelli; Emanuela Palmerini; Stefano Ferrari; Stefano Fanti; Pietro Ruggieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-12       Impact factor: 9.236

5.  [Cost considerations for whole-body MRI and PET/CT as part of oncologic staging].

Authors:  C Plathow; M Walz; M P Lichy; P Aschoff; C Pfannenberg; H Bock; S M Eschmann; C D Claussen; H P Schlemmer
Journal:  Radiologe       Date:  2008-04       Impact factor: 0.635

Review 6.  PET/CT in paediatric oncology: indications and pitfalls.

Authors:  Christiane Franzius; Kai Uwe Juergens
Journal:  Pediatr Radiol       Date:  2009-06

7.  Unusual abdominal metastases in osteosarcoma.

Authors:  Simon Berhe; Enrico Danzer; Paul Meyers; Gerald Behr; Michael P LaQuaglia; Anita P Price
Journal:  J Pediatr Surg Case Rep       Date:  2018-01

Review 8.  Imaging following surgery for primary appendicular bone tumours.

Authors:  Imran Khan; Craig Gerrand; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2021-01-22       Impact factor: 2.199

Review 9.  18F-PET-CT in extracranial paediatric oncology: when and for whom is it useful?

Authors:  Sue C Kaste
Journal:  Pediatr Radiol       Date:  2008-06

Review 10.  Imaging pediatric bone sarcomas.

Authors:  Sue C Kaste
Journal:  Radiol Clin North Am       Date:  2011-06-16       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.